Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
22.11% 0.68% (8.47%) (8.80%)

+8 more TTM periods

Piotroski F-Score
7 6 5 5
ROA
8.54% 0.25% (3.01%) (3.03%)
ROIC
8.06% (0.34%) (3.72%) (4.24%)
Return on Tangible Assets
48.26% 1.16% (16.77%) (21.41%)
Average Days of Receivables
69.88 68.77 71.05 67.10
Free Cash Flow per Share
22.41 5.07 5.18 6.28
Free Cash Flow
1,416.54 313.74 316.14 380.97
Capital Expenditures
(244.54) (1,020.44) (1,039.64) (1,010.86)
Other line items
Cash ROIC
12.48% 2.46% 2.61% 3.35%
Accounts Receivable Turnover
5.77 5.96 5.52 5.59
Accounts Payable Turnover
4.89 5.44 5.03 4.03
Inventory Turnover
1.12 1.15 1.12 0.94
Average Days of Payables
88.01 68.51 88.55 116.12
Days of Inventory on Hand
303.43 299.72 302.42 368.52
Tax Rate
0.29 (1.14) (0.43) (0.48)
Research and Development Expense of Revenue
17.73% 17.98% 18.34% 19.46%
Selling, General and Administrative Expense of Revenue
36.48% 37.13% 42.40% 42.63%
Share Based Compensation of Revenue
6.67% 6.71% 6.82% 6.99%
Interest Coverage
5.25 (0.21) (2.21) (2.46)
Operating CF/Net income
1.77 45.30 (3.81) (3.89)
Depreciation/Fixed assets
3.39 3.51 3.48 3.63
Capex/Depreciation
(0.34) (1.43) (1.49) (1.47)
Revenue per Share
72.81 71.71 69.98 68.50
Operating CF per Share
26.28 21.55 22.23 22.93
Capex per Share
(3.87) (16.49) (17.05) (16.65)
Capex to Sales
0.05 0.23 0.24 0.24

Fold the line items

Columns are period end dates